Regeneron Strikes Deal With Genentech To Market Eylea
Under the nonexclusive licensing agreement, Regeneron agreed to pay Roche Group unit Genentech $60 million until May 2016 if sales of Regeneron’s Eylea reached $400 million. Additionally, Regeneron said it had agreed to pay almost 5 percent in royalties if U.S. sales of Eylea were $400 million to $3 billion.
If U.S. sales...
To view the full article, register now.